Vue transversale de la maladie
Lupus
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
719 résultats correspondants
· 46 visibles sur cette page
dans le périmètre Lupus
Niveau clinique
Études et traitements 248
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Iptacopan (part 1) NCT05268289 · Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephrit… | Lupus | À vérifier | Phase 2 | RECRUITING | The overall purpose of this two-part study is to evaluate the efficacy, sa… À vérifier | ClinicalTrials.gov 2026-08-13 14:28:30 | Détail |
| Mycophenolate Mofetil NCT03490539 · PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | Myasthénie | À vérifier | À vérifier | COMPLETED | Glucocorticoids (GC) use has increased survival of patients with systemic… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:40 | Détail |
| Nipocalimab NCT04951622 · A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Myasthénie | À vérifier | Phase 3 | RECRUITING | The purpose of this study is to evaluate how well nipocalimab works as com… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:39 | Détail |
| Nipocalimab NCT07217587 · EPIC — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With… | Myasthénie | À vérifier | Phase 3 | RECRUITING | The purpose of this study is to evaluate how well nipocalimab works as com… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:38 | Détail |
| ADX-097 NCT06419205 · A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097… | Lupus | À vérifier | Phase 2 | RECRUITING | A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| BIIB059 (litifilimab) NCT06044337 · AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safety of Lit… | Lupus | Traitement symptomatique · Thérapie génique | Phase 3 | ENROLLING_BY_INVITATION | In this study, researchers will learn more about a study drug called BIIB0… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| CC-97540 NCT05869955 · A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Seve… | Lupus | Immunomodulation | Phase 1 | ACTIVE_NOT_RECRUITING | The purpose of this study is to establish the tolerability, preliminary ef… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| CC-97540 NCT07015983 · A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, i… | Lupus | Immunomodulation | Phase 2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to establish the tolerability, preliminary ef… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| ECHOS — Engagement in CHildhood-Onset Systemic Lupus NCT05693571 · NCT05693571 | Lupus | Traitement symptomatique | Non applicable | ACTIVE_NOT_RECRUITING | The goal of this observational (Aim 1) and pilot study (Aim 2) is to bette… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservatio… NCT05567198 · NCT05567198 | Lupus | Traitement symptomatique | À vérifier | RECRUITING | Background: Systemic lupus erythematosus (SLE) is a disease that affects f… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Hydroxychloroquine NCT05799378 · SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Lupus | Immunomodulation · Traitement symptomatique | Phase 3 | RECRUITING | Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% ch… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| LUPKYNIS NCT07611214 · PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in… | Lupus | À vérifier | Phase 4 | RECRUITING | The goal of this clinical study is to assess the efficacy and safety of LU… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Obecabtagene autoleucel (obe-cel) NCT06333483 · CARLYSLE — Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refra… | Lupus | Immunomodulation | Phase 1 | ACTIVE_NOT_RECRUITING | This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Obinutuzumab NCT05039619 · POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Ob… | Lupus | À vérifier | Phase 2 | RECRUITING | This phase II, randomized, double-blind, placebo-controlled study is desig… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| P-CD19CD20-ALLO1 Cells NCT06984341 · A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamic… | Lupus | Immunomodulation | Phase 1 | WITHDRAWN | The purpose of this study is to evaluate the safety and tolerability of P-… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| SNC116 NCT07748156 · SNC116 Therapy for Refractory Systemic Lupus Erythematosus | Lupus | À vérifier | Phase 1 | NOT_YET_RECRUITING | This study aims to evaluate the safety and tolerability of SNC116 in treat… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| ACG102 Injection NCT07749430 · A Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic… | Lupus | À vérifier | Phase 1 | NOT_YET_RECRUITING | The purpose of this study is to evaluate the safety, tolerability, pharmac… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| Anifrolumab NCT07751848 · LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Hav… | Lupus | À vérifier | Phase 3 | NOT_YET_RECRUITING | This is an observational study, in which the main research question is to… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| BI 3000202 NCT07409181 · A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic… | Lupus | À vérifier | Phase 2 | RECRUITING | This study is open to adults with systemic lupus erythematosus (SLE). The… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| Dapirolizumab pegol NCT04976322 · A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study… | Lupus | À vérifier | Phase 3 | ENROLLING_BY_INVITATION | The purpose of this study is to evaluate long-term safety and tolerability… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
Découverte scientifique
Recherches et trouvailles 0
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune trouvaille ne correspond aux filtres. | |||||||
Bibliographie
Publications 465
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Muscle toxicity reports in FAERS: a disproportionality analysis with… Atorvastatin · PMID 42440952 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source Muscle toxicity can significantly impair quality of life and may be life-threatening in severe cases. Although statins… | Frontiers in pharmacology 2026-07-14 16:03:16 | Source |
| Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arte… Atorvastatin · PMID 42439699 | Lupus | Ralentissement de la progression | Publication | PubMed | Voir la publication source Marfan syndrome (MFS) is characterized by progressive aortic aneurysm formation resulting from mutations in the fibrill… | Cells 2026-07-14 16:03:16 | Source |
| Gender-Based Differences in Clinical, Immunological and Disease Activ… Assessment of Blood Indices in Systemic Lupus Erythematosus · PMID 42375063 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with well-recognized female predominance; however, d… | Mymensingh medical journal : MMJ 2026-07-14 16:03:15 | Source |
| Peripheral blood immunoglobulin A level is independently negatively c… Assessment of Blood Indices in Systemic Lupus Erythematosus · PMID 42440243 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source Lupus nephritis is a key factor affecting the prognosis of childhood-onset systemic lupus erythematosus (SLE). Immunogl… | Clinical rheumatology 2026-07-14 16:03:15 | Source |
| Anti-SMN complex antibodies in paediatric mixed connective tissue dis… Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic… | Lupus | Thérapie cellulaire | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Rheumatology advances in practice 2026-07-14 16:03:14 | Source |
| Large Pericardial Effusion As the Initial Presentation of Mixed Conne… Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic… | Lupus | Immunomodulation · Traitement symptomatique · Thérapie cellulaire | Publication | PubMed | Voir la publication source Pericardial effusion, defined as the abnormal accumulation of fluid within the pericardial sac, has a broad differentia… | Cureus 2026-07-14 16:03:14 | Source |
| Management of Uncomplicated Plasmodium vivax Malaria in a Pregnant Pa… Hydroxychloroquine · PMID 42441108 | Lupus | Traitement symptomatique | Publication | PubMed | Voir la publication source is one of the most common forms of malaria worldwide, notable for its ability to relapse from a dormant liver stage. Ra… | Cureus 2026-07-14 16:03:04 | Source |
| Purpura as the initial manifestation of IgG4-related disease with con… Hydroxychloroquine · PMID 42440567 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Purpura is a common clinical manifestation of a wide variety of diseases, including extremely uncommon conditions. In t… | Frontiers in medicine 2026-07-14 16:03:04 | Source |
| Selpercatinib versus multi-kinase inhibitors for advanced medullary t… Cabozantinib · PMID 42440541 | Lupus | Ralentissement de la progression | Publication | PubMed | Voir la publication source Several -targeted agents, including highly selective inhibitors (SRIs) and multi-kinase inhibitors (MKIs), have been ap… | Frontiers in endocrinology 2026-07-14 16:02:53 | Source |
| Breakthrough reactions in pediatric chemotherapeutic desensitization:… Cyclophosphamide · PMID 42444056 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Rapid drug desensitization (RDD) enables the safe reintroduction of chemotherapeutic agents in patients with hypersensi… | Pediatric allergy and immunology : official publicatio… 2026-07-14 16:02:46 | Source |
| Multi-omics integration reveals that pterostilbene ameliorates cyclop… Cyclophosphamide · PMID 42444162 | Lupus | Neuroprotection · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Cyclophosphamide (CTX) is a commonly used immunosuppressant and chemotherapeutic drug; however, its clinical applicatio… | Food & function 2026-07-14 16:02:46 | Source |
| Multi-omics-guided diagnosis and treatment of toxoplasma retinochoroi… Prednisone · PMID 42436394 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Toxoplasma retinochoroiditis is challenging to diagnose and treat, especially in immunocompromised or co-infected indiv… | BMC ophthalmology 2026-07-12 19:42:50 | Source |
| Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome… Rituximab · PMID 42437162 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source Kidney outcomes in children with steroid-resistant nephrotic syndrome (SRNS) following rituximab remain unclear. We con… | Kidney international reports 2026-07-12 19:42:44 | Source |
| Immunomodulatory Effects of Volatile Anesthetic Sevoflurane on Cardio… Anti-CD19-CD3E-CAR-T cells · PMID 42437319 | Lupus | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Volatile anesthetics, particularly sevoflurane, have demonstrated cardioprotective properties during cardiac surgery. H… | Iranian journal of allergy, asthma, and immunology 2026-07-12 19:42:08 | Source |
| Regulation of AQP4 Expression and Investigation of the Underlying Mec… Anti-CD19-CD3E-CAR-T cells · PMID 42437320 | Lupus | Immunomodulation · Thérapie cellulaire · Thérapie génique | Publication | PubMed | Voir la publication source Human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) remains a major neurological complication… | Iranian journal of allergy, asthma, and immunology 2026-07-12 19:42:08 | Source |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Ianalumab · PMID 42384883 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | The New England journal of medicine 2026-07-12 19:42:07 | Source |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply. Ianalumab · PMID 42384884 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | The New England journal of medicine 2026-07-12 19:42:07 | Source |
| Anti-Ficolin-2 and Anti-Ficolin-3 Autoantibody Detection by ELISA. Anti-ficolin-3 Autoantibodies in Lupus Nephritis · PMID 33847937 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Ficolins are recognition proteins of the lectin pathway of the complement system and also play an important role in inn… | Methods in molecular biology (Clifton, N.J.) 2026-07-12 19:42:06 | Source |
| Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Pa… Anti-ficolin-3 Autoantibodies in Lupus Nephritis · PMID 29045037 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various aut… | Arthritis care & research 2026-07-12 19:42:06 | Source |
| Chorea as a Non-Thrombotic Manifestation in an Adolescent with System… prednisolone and mycophenolate mofetil · PMID 42428154 | Lupus | Traitement symptomatique | Publication | PubMed | Voir la publication source Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombo… | Case reports in neurology 2026-07-12 19:42:05 | Source |
Exploration — prudence
Pistes exploratoires 6
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Lupus | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation immunométabolique de la microglie 4-octyl itaconate et dérivés est étudié dans Sclérose latérale amyotrophique et documente plusieurs axes biologiques po… | Rapprochement Biomedical Watch · Sclérose latérale amy… | Détail |
| Bavisant BRAVEinMS — Bavisant | Lupus | Remyélinisation · Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Antagonisme du récepteur H3 de l’histamine Bavisant est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pour Lupus… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| Vecteur Ple389 (ADORA2A) MiniPromoter Ple389 — ciblage striatal | Lupus | Thérapie génique | Hypothèse exploratoire | Rapprochement automatique non validé | Expression génique ciblée dans les neurones striataux Vecteur Ple389 (ADORA2A) est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être per… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| Tol-MP Tol-MP — tolérance immunitaire spécifique de la myéline | Lupus | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Microparticules biodégradables chargées en rapamycine et fonctionnalisées… Tol-MP est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pour Lupus :… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| SetPoint System SetPoint System — SetPoint Medical | Lupus | Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | re ApplicationsPublicationsCompanyCareersNewsGet startedGet startedNewsThe… SetPoint System est étudié dans Sclérose en plaques et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Sclérose en plaques | Détail |
| Thonningianin A Thonningianin A — neuroprotection anti-amyloïde | Lupus | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation du stress oxydatif et des protéines associées à Alzheimer Thonningianin A est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |